Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03597516 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance
A Phase 3 study, sponsored by Ritter Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 557
- Enrollment target
NCT03597516 is a Phase 3 study that has completed, run by Ritter Pharmaceuticals. The registered enrollment target is 557 participants.
The verdict
NCT03597516, a Phase 3 study, has completed, sponsored by Ritter Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 557 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study conducted in the United States (US) to assess the efficacy of RP-G28 compared to placebo on symptom reduction related to lactose intolerance.
Interventions
- DRUG Placebos
- DRUG RP-G28
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 557 participants |
| Start Date | 2018-06-26 |
| Est. Completion | 2019-07-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03597516
The ClinicalTrials.gov registry entry for NCT03597516 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 557 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ritter Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03597516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03597516 about?
NCT03597516 is a clinical study titled "Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance". This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study conducted in the United States (US) to assess the efficacy of RP-G28 compared to placebo on symptom reduction related to lactose intolerance.
What is the current status of trial NCT03597516?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 557 participants. The study started on 2018-06-26. Estimated completion is 2019-07-02.
What interventions are being tested in trial NCT03597516?
The interventions under investigation include: Placebos (DRUG), RP-G28 (DRUG).
Who is sponsoring clinical trial NCT03597516?
This trial is sponsored by Ritter Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.